Details of Disease

General Information of Disease (ID: DIS6M7AN)

Disease Name Psoriasis vulgaris
Disease Class EA90: Psoriasis
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DIS6M7AN: Psoriasis vulgaris
ICD Code
ICD-11
ICD-11: EA90
ICD-10
ICD-10: L40
Expand ICD-11
EA90
Expand ICD-10
L40
Expand ICD-9
140,141,142,143,144,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000
Disease Identifiers
MedGen ID
537842
SNOMED CT ID
200975007

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 27 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Acitretin DM8BKU9 Approved Small molecular drug [1]
Ammoniated mercury DMJYVKF Approved Small molecular drug [2]
Apremilast DMTWS9E Approved Small molecular drug [3]
Azaribine DM9T7U5 Approved Small molecular drug [2]
Belumosudil DM548TK Approved NA [4]
Brodalumab DMASDQ6 Approved Monoclonal antibody [5]
Calcipotriol DM03CP7 Approved Small molecular drug [6]
Ciclosporin DMAZJFX Approved NA [7]
Coal tar DM89MJH Approved NA [2]
Deucravacitinib DMAR1YS Approved NA [8]
Dithranol DM79JHD Approved Small molecular drug [2]
Efalizumab DMCKL5V Approved Antibody [9]
Lestaurtinib DMQ2AIJ Approved (orphan drug) Small molecular drug [10]
Methoxsalen DME8FZ9 Approved Small molecular drug [11]
Mirikizumab DM7R3N5 Approved NA [4]
Ponesimod DMEAOYJ Approved Small molecular drug [12]
Spesolimab DM9FZYT Approved NA [13]
Tacalcitol DMQHZE9 Approved Small molecular drug [14]
Tapinarof DMRPI2Q Approved NA [15]
Tazarotene DM8SMD1 Approved Small molecular drug [16]
Ustekinumab DMHTYK3 Approved Antibody [17]
Valrubicin DMOYJFK Approved Small molecular drug [2]
Verteporfin DMIY6DB Approved Small molecular drug [2]
Voclosporin DMWIJTN Approved Small molecular drug [18]
Xp-828l DMSQ478 Approved NA [2]
LEO 80185 DM7XLJU Phase 4 Small molecular drug [19]
NPS-31807 DMIYBGZ Phase 4 NA [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 27 Drug(s)
This Disease is Treated as An Indication in 71 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
5-methoxypsoralen DME2A8X Phase 3 Small molecular drug [21]
ARQ-151 DML61S4 Phase 3 Small molecular drug [22]
ASP-015K DMZ1UOI Phase 3 Small molecular drug [23]
E-0116 DM0BAHV Phase 3 NA [24]
IB-MECA DM9G5XD Phase 3 Small molecular drug [25]
M-518101 DMZ6VD5 Phase 3 NA [26]
MK-3222 DMQBF7O Phase 3 Antibody [27]
RAVAX DMGJ8ES Phase 3 NA [28]
Serlopitant DM5VH6U Phase 3 NA [4]
Apo805K1 DMON7OL Phase 2 NA [29]
Ascrolimus DMZF68E Phase 2 NA [30]
Bertilimumab DMRC0EQ Phase 2 Monoclonal antibody [25]
BFH-772 DMVUX1C Phase 2 NA [31]
BIM23A760 DM6EIZG Phase 2 Small molecular drug [32]
BMS-582949 DMGYXFP Phase 2 Small molecular drug [33]
BMS-986020 DMHMV6E Phase 2 NA [25]
BT-061 DM2LZIY Phase 2 Antibody [34]
BTT-1023 DMIEPJG Phase 2 Antibody [35]
CMI-392 DM1NCUY Phase 2 Small molecular drug [36]
CT 327 DMQXL1T Phase 2 NA [37]
DPS-102 DMRY66N Phase 2 NA [38]
E6201 DMOSL9P Phase 2 Small molecular drug [39]
Elisidepsin DMB38KH Phase 2 NA [40]
Fezakinumab DMJX2P4 Phase 2 Antibody [41]
GSK2982772 DM7HNFV Phase 2 NA [25]
IMO-3100 DMM549D Phase 2 NA [42]
IP10 C8 DMANRGW Phase 2 NA [43]
IR502 DMW2IF9 Phase 2 NA [44]
LEO 22811 DM2Q332 Phase 2 NA [45]
LEO 90100 DMQH88Z Phase 2 NA [46]
LEO-32731 DMZ6Y0T Phase 2 NA [47]
LL-4218 DMFDT71 Phase 2 NA [48]
LLL-3348 DMOEZPJ Phase 2 NA [49]
Lunacalcipol DMLRU9I Phase 2 Small molecular drug [50]
MK-0873 DM0568C Phase 2 Small molecular drug [51]
NN-8226 DMKD5ZO Phase 2 Antibody [52]
PF-06700841 DMMGSFV Phase 2 NA [25]
PH-10 DMFXGMB Phase 2 NA [25]
Rambazole DMP2DNS Phase 2 Small molecular drug [18]
RVT-505 DM3C9F8 Phase 2 NA [4]
Santalum DMM9KK9 Phase 2 NA [4]
Santalum album DMA1UPY Phase 2 NA [25]
Siplizumab DM75RFJ Phase 2 Antibody [53]
VB-201 DMGJR0Y Phase 2 NA [54]
VTP-43742 DMCA8G1 Phase 2 NA [25]
COVA322 DM824EG Phase 1/2a Monoclonal antibody [55]
Dalazatide DMJ1NG4 Phase 1b/2a NA [56]
Debio-0824 DMV401D Phase 1b/2a NA [56]
ART621 DMI17NX Phase 1/2 NA [18]
AS-210 DMJR88S Phase 1/2 NA [57]
ALX-0761 DMJ8ACF Phase 1 Monoclonal antibody [58]
ARN-6039 DM4D85V Phase 1 NA [25]
AST-005 DMCN7WI Phase 1 NA [4]
BAY1834845 DM8V62T Phase 1 NA [4]
BBI-6000 DMTG9WM Phase 1 NA [4]
BCT-194 DM2WEY1 Phase 1 NA [59]
CC-90006 DMHJLB6 Phase 1 Antibody [4]
CM2489 DMMC6YR Phase 1 NA [60]
EDP1066 DMPUE9M Phase 1 NA [4]
ILV-095 DMQ01MP Phase 1 Antibody [61]
JNJ-3534 DM49VWQ Phase 1 NA [4]
LEO-27989 DMYLNON Phase 1 NA [62]
LY3316531 DMRQWRQ Phase 1 NA [4]
ONS-3010 DMVMZ8M Phase 1 NA [25]
Pc4 DM23K45 Phase 1 NA [63]
PF-06263276 DM5YG02 Phase 1 NA [64]
PRX003 DM5KI6X Phase 1 NA [25]
SAFINGOL DMBGUDR Phase 1 Small molecular drug [65]
SB414 DMB834E Phase 1 NA [4]
SNA-125 DM8L1GJ Phase 1 NA [4]
XCUR17 DM11XUT Phase 1 NA [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 71 Drug(s)
This Disease is Treated as An Indication in 5 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
PMID27998201-Compound-5 DMVZ0ND Patented Small molecular drug [66]
Quinazoline derivative 10 DMZ3ORT Patented Small molecular drug [67]
Quinazoline derivative 11 DMAH435 Patented Small molecular drug [67]
Quinazoline derivative 12 DMVKZU2 Patented Small molecular drug [67]
VX-148 DML32R8 Patented Small molecular drug [68]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 28 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Etarotene DM3OUT0 Discontinued in Phase 3 Small molecular drug [69]
IRX-4310 DMUYQH8 Discontinued in Phase 3 NA [70]
Atocalcitol DM7OE9F Discontinued in Phase 2 Small molecular drug [71]
BAL-2299 DMH5QKP Discontinued in Phase 2 NA [72]
BIRT 2584 DMU59UK Discontinued in Phase 2 NA [73]
BMS-587101 DMS2IC9 Discontinued in Phase 2 NA [73]
FPL-64170 DML6MVP Discontinued in Phase 2 NA [74]
IC-747 DM1LVRP Discontinued in Phase 2 NA [75]
KC706 DMBX6C7 Discontinued in Phase 2 NA [76]
LAS-37779 DM9J6BX Discontinued in Phase 2 NA [77]
PVAC DM1A84M Discontinued in Phase 2 NA [78]
R-68151 DM2NTJY Discontinued in Phase 2 Small molecular drug [79]
SB-201993 DMIF4VJ Discontinued in Phase 2 Small molecular drug [80]
SDZ-LAP-977 DMX4938 Discontinued in Phase 2 NA [81]
Tisocalcitate DMGF35T Discontinued in Phase 2 Small molecular drug [82]
TU-2100 DMA14FD Discontinued in Phase 2 NA [83]
VML-262 DMJA5A1 Discontinued in Phase 2 NA [84]
ALS-00T2-0501 DM2QMKJ Discontinued in Phase 1 NA [85]
CCX-832 DMD8QHV Discontinued in Phase 1 NA [86]
PD-153035 DM7KJTI Discontinued in Phase 1 Small molecular drug [87]
SB 235699 DMNH8XU Discontinued in Phase 1 Small molecular drug [88]
AD-177 DMFPHBG Terminated NA [91]
DB-200 DMTXPSB Terminated NA [92]
Hu Dreg 55 DMK1VHF Terminated Antibody [93]
MOR-102 DMRCH1M Terminated Antibody [94]
R348 DM12EYR Terminated NA [18]
SB-209247 DMVBNTP Terminated Small molecular drug [95]
YP-008 DM2N76V Terminated NA [96]
------------------------------------------------------------------------------------
⏷ Show the Full List of 28 Drug(s)
This Disease is Treated as An Indication in 3 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
CLS008 DMNXLTO Application submitted NA [4]
RAP-160 DMUTVOB Preclinical NA [89]
VCB102 DMR3XDH Preclinical Small molecular drug [90]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 17 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Amphiregulin targeting human mabs DM7HH87 Investigative Monoclonal antibody [97]
Ankinara DMZKC7S Investigative NA [98]
ASB-16165 DM0YHO8 Investigative Small molecular drug [97]
AZ-17 DMI8S20 Investigative NA [97]
BL-7020 DME3LWJ Investigative NA [97]
CXCL8 DMG1SXD Investigative Small molecular drug [97]
DM-512 DMXY90Y Investigative NA [97]
DPS-151 DMCSKJ3 Investigative NA [97]
FM-301 DM5PZZF Investigative NA [97]
GSK-2263167 DMERNWP Investigative NA [97]
Hairpin RNA DMX9Q71 Investigative NA [97]
KIN-4050 DMBWYRW Investigative NA [97]
KM-133 DMXFKZV Investigative Small molecular drug [97]
LEO-90110 DMGW9WN Investigative NA [97]
LPD-1050 DMB1XEP Investigative NA [97]
PU-2049 DMBQW18 Investigative NA [97]
X-083-NAB DMFZMPI Investigative NA [97]
------------------------------------------------------------------------------------
⏷ Show the Full List of 17 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7598).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7372).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7540).
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2778).
7 Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007 May;19(3):238-45.
8 ClinicalTrials.gov (NCT04036435) Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis.. U.S. National Institutes of Health.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6593).
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5672).
11 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009048.
12 ClinicalTrials.gov (NCT00852670) ACT-128800 in Psoriasis. U.S. National Institutes of Health.
13 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761244.
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2780).
15 ClinicalTrials.gov (NCT01098734) Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream. U.S. National Institutes of Health.
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6952).
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6885).
18 Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
19 ClinicalTrials.gov (NCT00924950) Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis. U.S. National Institutes of Health.
20 ClinicalTrials.gov (NCT01373567) A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis. U.S. National Institutes of Health.
21 ClinicalTrials.gov (NCT00533195) Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis. U.S. National Institutes of Health.
22 ClinicalTrials.gov (NCT04746911) Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216). U.S. National Institutes of Health.
23 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8315).
24 Biopharmaceutical Research Companies Are Developing Nearly 300 Medicines to Treat Diseases of the Skin. MEDICINES IN DEVELOPMENT FOR Skin Diseases 2011.
25 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
26 ClinicalTrials.gov (NCT01989429) Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients. U.S. National Institutes of Health.
27 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8093).
28 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006246)
29 ClinicalTrials.gov (NCT01483924) Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis. U.S. National Institutes of Health.
30 Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation. 2014 Mar 27;97(6):636-41.
31 ClinicalTrials.gov (NCT01449591) Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients. U.S. National Institutes of Health.
32 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003802)
33 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7838).
34 ClinicalTrials.gov (NCT01072383) Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis. U.S. National Institutes of Health.
35 ClinicalTrials.gov (NCT02239211) A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis. U.S. National Institutes of Health.
36 Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20.
37 ClinicalTrials.gov (NCT01808157) A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis. U.S. National Institutes of Health.
38 ClinicalTrials.gov (NCT01368887) Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis. U.S. National Institutes of Health.
39 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7836).
40 First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs. 2015 Aug;33(4):901-10.
41 ClinicalTrials.gov (NCT01941537) Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis. U.S. National Institutes of Health.
42 ClinicalTrials.gov (NCT01622348) Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis. U.S. National Institutes of Health.
43 Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47(3):253-61.
44 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
45 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028044)
46 ClinicalTrials.gov (NCT01600222) Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris. U.S. National Institutes of Health.
47 ClinicalTrials.gov (NCT01310049) LEO 32731 - A Study in Healthy Male Subjects. U.S. National Institutes of Health.
48 Clinical pipeline report, company report or official report of Lupin Ltd.
49 Clinical pipeline report, company report or official report of Lupin Ltd.
50 ClinicalTrials.gov (NCT01453634) Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018). U.S. National Institutes of Health.
51 ClinicalTrials.gov (NCT00132730) An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005). U.S. National Institutes of Health.
52 ClinicalTrials.gov (NCT02097264) A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. U.S. National Institutes of Health.
53 Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52.
54 ClinicalTrials.gov (NCT01001468) Study to Assess VB-201 in Patients With Psoriasis. U.S. National Institutes of Health.
55 ClinicalTrials.gov (NCT02243787) Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis
56 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
57 ClinicalTrials.gov (NCT02360358) Autologous Skin Substitute for Chronic Leg/Foot Ulcers.. U.S. National Institutes of Health.
58 ClinicalTrials.gov (NCT02156466) Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects
59 ClinicalTrials.gov (NCT01539915) Pharmacokinetics and Pharmacodynamics of BCT194 in Psoriatic Patients. U.S. National Institutes of Health.
60 Clinical pipeline report, company report or official report of CalciMedica (2011).
61 ClinicalTrials.gov (NCT01010542) Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects. U.S. National Institutes of Health.
62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033794)
63 Association between the photodynamic loss of Bcl-2 and the sensitivity to apoptosis caused by phthalocyanine photodynamic therapy. Photochem Photobiol. 2003 Jul;78(1):1-8.
64 ClinicalTrials.gov (NCT01981681) A Phase 1 Study To Evaluate Tolerability, Safety, And Pharmacokinetics Of Topical PF-06263276 In Healthy Subjects. U.S. National Institutes of Health.
65 ClinicalTrials.gov (NCT00084812) Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
66 Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
67 Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
68 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013965)
69 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003576)
70 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009573)
71 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014844)
72 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016543)
73 Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
74 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005063)
75 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015378)
76 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023346)
77 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022894)
78 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011840)
79 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003630)
80 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003335)
81 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004738)
82 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018814)
83 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013307)
84 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008645)
85 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023971)
86 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025006)
87 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005268)
88 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012315)
89 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036946)
90 Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317.
91 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015044)
92 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026687)
93 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004232)
94 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017213)
95 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006734)
96 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026448)
97 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
98 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.